Výsledky vyhledávání - "Keita, Kameda"

Contribution of Identification of Adverse Events after Sharing Patient Information between Hospital and Community Pharmacies Using the Monitoring Sheet of S-1

Autor: Mamoru Tanaka, Kiyoshi Furukawa, Kiyoshi Kinoshita, Hitomi Sakai, Keita Kameda, Akiko Yano, Yuki Okada, Hiroaki Araki, Akihiro Tanaka, Tazu Hashioka, Hitoshi Kawazoe, Saya Shiraishi

Publikováno v: Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 43:94-103

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d8fe2763380ce0b67dd06c2e0433e47c
https://doi.org/10.5649/jjphcs.43.94

Zobrazit plný text záznamu

[Effect of dexamethasone on vascular pain caused by the administration of fosaprepitant dimeglumine and epirubicin hydrochloride in patients with primary breast cancer]

Autor: Keita, Kameda, Takayoshi, Kiba, Yoshikazu, Ogawa, Shizue, Kimoto, Sayoko, Kajiume, Yuuko, Okada, Nao, Morii, Hirotoshi, Takahashi, Yasunori, Ichiba, Hiroyasu, Yamashiro

Publikováno v: Gan to kagaku ryoho. Cancerchemotherapy. 41(10)

Epirubicin hydrochloride injection is indicated as a therapy for patients with primary breast cancer. This drug has been reclassified as a drug with high emetic potential according to the American Society of Clinical Oncology Guidelines for Antiemeti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::61cc65e2160c8f9eec76f30caf2bcffb
https://pubmed.ncbi.nlm.nih.gov/25335710

Zobrazit plný text záznamu

Akademický článek

Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival.

Autor: Takayoshi Kiba, Takuo Ito, Toshihisa Nakashima, Yoshiko Okikawa, Miki Kido, Akiko Kimura, Keita Kameda, Fumiaki Miyamae, Suzuko Tanaka, Misao Atsumi, Yoko Sumitani, Yoshimi Shitakubo, Hiromasa Niimi

Publikováno v: BMC Cancer; 2014, Vol. 14 Issue 1, p160-177, 18p

Zobrazit plný text záznamu

Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival

Autor: Misao Atsumi, Fumiaki Miyamae, Akiko Kimura, Takayoshi Kiba, Suzuko Tanaka, Toshihisa Nakashima, Keita Kameda, Takuo Ito, Yoshimi Shitakubo, Miki Kido, Yoshiko Okikawa, Hiromasa Niimi, Yoko Sumitani

Publikováno v: BMC Cancer

Background Bortezomib offers a novel approach to the treatment of multiple myeloma producing rapid control. The aim of this study was to investigate the outcomes of bortezomib and dexamethasone-treated patients with multiple myeloma. Methods We condu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f76338ab06b0d754292b28af9289b90

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání